Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Rated “Moderate Buy” by Wall Street Brokerages

Posted by Stanley Muller on Oct 5th, 2026

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $140.67.

Several equities research analysts recently commented on RYTM shares. TD Cowen reaffirmed a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, June 17th. Stifel Nicolaus set a $133.00 target price on Rhythm Pharmaceuticals in a research report on Monday, June 15th. Canaccord Genuity Group set a $154.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 5th. Royal Bank Of Canada raised their price target on shares of Rhythm Pharmaceuticals from $141.00 to $155.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Finally, National Bank Financial set a $160.00 price objective on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th.

Get Our Latest Research Report on Rhythm Pharmaceuticals

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CEO David Meeker sold 50,000 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $102.67, for a total value of $5,133,500.00. Following the completion of the sale, the chief executive officer owned 239,258 shares of the company’s stock, valued at approximately $24,564,618.86. The trade was a 17.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joseph Shulman sold 5,079 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $119.75, for a total value of $608,210.25. Following the transaction, the insider directly owned 15,915 shares in the company, valued at $1,905,821.25. The trade was a 24.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 258,450 shares of company stock valued at $28,796,497 in the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RYTM. EverSource Wealth Advisors LLC grew its stake in shares of Rhythm Pharmaceuticals by 303.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares during the period. GAMMA Investing LLC increased its position in shares of Rhythm Pharmaceuticals by 36.3% during the 2nd quarter. GAMMA Investing LLC now owns 364 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of Rhythm Pharmaceuticals in the 2nd quarter worth approximately $51,000. State of Wyoming lifted its stake in shares of Rhythm Pharmaceuticals by 155.9% in the 4th quarter. State of Wyoming now owns 2,441 shares of the company’s stock worth $261,000 after purchasing an additional 1,487 shares during the period. Finally, Centaurus Financial Inc. purchased a new position in shares of Rhythm Pharmaceuticals in the second quarter worth approximately $272,000.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM opened at $92.83 on Wednesday. Rhythm Pharmaceuticals has a twelve month low of $74.50 and a twelve month high of $122.20. The company has a market capitalization of $6.36 billion, a P/E ratio of -29.85 and a beta of 2.01. The firm has a 50 day moving average of $105.42 and a 200 day moving average of $97.67.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.08. Rhythm Pharmaceuticals had a negative return on equity of 159.87% and a negative net margin of 85.59%.The business had revenue of $71.25 million for the quarter, compared to analysts’ expectations of $67.66 million. During the same period in the prior year, the firm posted ($0.75) EPS. The firm’s quarterly revenue was up 46.9% on a year-over-year basis. On average, sell-side analysts expect that Rhythm Pharmaceuticals will post -2.86 EPS for the current year.

Rhythm Pharmaceuticals Company Profile

(Get Free Report)

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases of obesity and other disorders involving the melanocortin-4 receptor (MC4R) pathway. The company’s research is centered on conditions in which genetic defects disrupt the body’s regulation of appetite, hunger and energy expenditure.

Rhythm’s lead product is IMCIVREE (setmelanotide), an MC4R agonist designed to restore signaling in the brain’s melanocortin pathway.